Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

FKB327 was approved by the European Medicines Agency as a biosimilar to European‐authorized adalimumab (Humira(®); AbbVie Inc). Adalimumab is a monoclonal antibody, binding and inhibiting tumor necrosis factor (TNF)‐α with use indicated for several immune‐mediated, chronic, and inflammatory disorder...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Stefan, Yamamoto, Katsuhiko, Muniz, Rafael, Iwura, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272391/
https://www.ncbi.nlm.nih.gov/pubmed/32500668
http://dx.doi.org/10.1002/prp2.604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272391/
https://www.ncbi.nlm.nih.gov/pubmed/32500668
http://dx.doi.org/10.1002/prp2.604

Ejemplares similares